How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about etranacogene dezaparvovec

Marketing authorisation indication

2.1 Etranacogene dezaparvovec (Hemgenix, CSL Behring) has a conditional marketing authorisation 'for the treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for etranacogene dezaparvovec.

Price

2.3 The list price per treatment for a single dose of etranacogene dezaparvovec is £2,600,000.

2.4 The company has a commercial arrangement, which would have applied if etranacogene dezaparvovec had been recommended.